Abridged NCD Guidelines: Diabetes, Asthma & Hypertension

Objectives

The guidelines provide an integrated, people-centred framework for prevention, early detection, treatment and long-term management of non-communicable diseases and injuries in Liberia, principally diabetes, hypertension, asthma and cardiovascular disease, while recognising chronic conditions addressed through the PEN-Plus approach, including sickle cell disease, rheumatic heart disease and congenital heart disease.[1][2]They support Universal Health Coverage, health equity and incorporation of services into primary healthcare across health-system levels.[1]

• Strengthen programmatic standards for diagnosis, treatment, patient support and referral, and inform planning, budgeting, operations, essential medicines and equipment, workforce training and provider competencies.[2]
• Prevent and manage diabetes through healthy diets, physical activity, weight management, smoking avoidance, psychosocial support, glucose-lowering medicines and insulin.[3]
• Improve diabetes care throughout pregnancy by identifying pre-existing and gestational diabetes, controlling maternal glucose and reducing risks to mothers and babies.[4][3]
• Integrate management of diabetes, tuberculosis and HIV to improve early detection, glycaemic control, infection outcomes, viral suppression and survival.[5][6]
• Reduce asthma symptoms, exacerbations, morbidity and mortality through early diagnosis, patient education, trigger avoidance and severity-responsive long-term treatment.[7][8][9]
• Reduce hypertension-related illness, disability, mortality and cardiovascular risk through accessible detection, consistent monitoring, lifestyle change and appropriate medical management.[10][11]
• Prevent further cardiovascular events among people with established cardiovascular disease through secondary prevention, blood-pressure control, statin treatment where indicated, antiplatelet therapy where appropriate and adherence support.[12][13]

The available material is primarily a clinical guideline rather than a costed national implementation plan. It does not provide a complete document-level set of measurable strategic targets, budgets or financing allocations.[14][1][2]

Implementation

Implementation is intended through integrated primary and secondary care, delivered by multidisciplinary teams and linked through longitudinal care, mentorship and referral support.[2]The guidance is directed at policymakers, programme managers, healthcare providers and partners, including clinicians, mental-health and social workers involved in primary-level patient care.[1][2]Development involved the Ministry of Health, its Non-Communicable Diseases and Injuries Unit, a Technical Working Group, clinical experts, providers and development partners.[1][15]

• Integrate non-communicable disease services into primary healthcare and apply the World Health Organization Package of Essential Noncommunicable Disease Interventions alongside the PEN-Plus approach for more complex chronic conditions.[1][2]
• Use multidisciplinary teams of doctors, nurses, physician assistants, midwives and other health workers to provide continuing care, patient support and referrals.[2]
• Screen adults aged 30 years and above, and people with recognised risk factors, for diabetes and hypertension; use appropriate glucose testing, blood-pressure measurement and clinical assessment to confirm diagnoses.[16][10][11]
• Provide structured diabetes care through lifestyle interventions, oral glucose-lowering medicines, insulin and combination treatment, escalating therapy and arranging urgent referral for ketoacidosis, hyperosmolar states, severe hypoglycaemia and other defined high-risk presentations.[3][17]
• Coordinate antenatal, labour and postnatal care for pregnant people with diabetes through midwifery and obstetric and gynaecology services, with glucose monitoring, insulin where appropriate and newborn glucose monitoring.[4][3]
• Screen people with diabetes for tuberculosis symptoms and offer HIV testing in accordance with national algorithms; screen people living with HIV for diabetes at diagnosis, before antiretroviral therapy and annually thereafter.[5][6]
• Establish one-stop or closely coordinated tuberculosis, HIV and non-communicable disease services where feasible, using harmonised appointments, shared records and coordination between clinics.[5][6]
• Support continuity of diabetes and HIV care through treatment literacy, peer groups, mental-health support and community-health-worker follow-up, including attention to dual stigma.[6][7]
• Apply stepwise asthma care using reliever medicines, inhaled corticosteroids as preferred anti-inflammatory treatment, appropriate device and spacer use, trigger avoidance, periodic review and referral for severe exacerbations.[9][18]
• Deliver hypertension and cardiovascular care through repeated blood-pressure measurement, cardiovascular-risk assessment, lifestyle counselling, stepped antihypertensive treatment, timely management of hypertensive emergencies and secondary prevention for established disease.[19][20][21][13]

Clinical follow-up relies on condition-specific measurements and review: blood glucose and glycated haemoglobin for diabetes, blood pressure and renal function for hypertension, inhaler technique and symptoms for asthma, and treatment, viral-load and complication review for people living with HIV and diabetes.[6][9][20]Formal programme-level indicators, reporting schedules, surveillance arrangements and accountability mechanisms are not specified in the supplied extracts.[14][1][15]

Monitoring & Evaluation

Monitoring in the guideline is predominantly clinical and patient-level, covering diagnosis, treatment adjustment, complications, acute emergencies and follow-up across diabetes, tuberculosis (TB), HIV, asthma, hypertension and cardiovascular disease. A formal document-wide monitoring and evaluation framework, programme targets, routine reporting system, surveillance architecture, audit process and accountability mechanism are not specified in the supplied extracts.[14][1][15][22][23][24]

• Monitor diabetes through blood glucose testing, glycated haemoglobin, complication assessment and patient-held glucose logs used to adjust insulin doses.[16][25][26][27]
• Use age-specific glycated haemoglobin targets for children with type 1 diabetes: below 8.5 for children under 6 years, below 8 for those aged 6 to 12 years, and below 7.5 for those aged 13 years and above.[25]
• Undertake intensive bedside monitoring during diabetic ketoacidosis, including hourly vital signs, consciousness, blood glucose and fluid balance, plus electrolyte and potassium testing every six hours.[28][29][30][31]
• Screen and monitor diabetes in pregnancy through gestational-diabetes testing, finger-stick glucose checks, specified pregnancy glucose targets, delivery glucose control and serial newborn glucose monitoring.[4][3]
• Monitor people receiving integrated HIV and diabetes care through blood glucose at every visit, glycated haemoglobin every three to six months, blood pressure and foot health at each visit, annual lipid and renal assessment, and HIV viral-load monitoring under HIV guidance.[6]
• Assess asthma severity using symptoms, night-time waking, reliever use, activity limitation and lung function; review inhaler use and stable patients every six months, while monitoring medicine-specific risks during treatment.[8][9][32][33][34]
• Measure blood pressure repeatedly to diagnose and classify hypertension, review treatment response every two to four weeks during dose adjustment, and monitor renal function after dose escalation with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.[10][11][19][20]
• Follow people with established cardiovascular disease every three to six months, review adherence and symptoms, and conduct annual cardiovascular-risk, diabetes and kidney-disease assessment.[12][13]
• Monitor children with elevated blood pressure or uncomplicated stage 1 hypertension every three to six months, with more frequent review after medicines are started and continuing electrocardiography where left ventricular hypertrophy has occurred.[35][36]

Costing & Financing

The extracts provide very limited financial information. They identify planning, budgeting, medicines, equipment, training and provider competencies as operational requirements, but do not provide a consolidated budget, costed implementation plan, expenditure figures, allocations, quantified funding gap, resource-mobilisation strategy or economic assumptions.[2][14][1][15]

• Recognise that guideline development received financial and logistical support from funding agencies and development partners, with the World Diabetes Foundation specifically acknowledged among supporters.[1][15]
• Note that the guideline's focus on diabetes and hypertension is supported by World Diabetes Foundation funding.[2]
• Plan for essential medicines, equipment, training and workforce competencies as stated operational inputs for primary- and secondary-level management of diabetes, hypertension and asthma.[2]
• Account for differing resource requirements between insulin regimens, as some options require one to three glucose test strips daily and glargine-based treatment may be more expensive.[37][38]
• Consider the direction to use the cheapest available inhaled corticosteroid where clinically appropriate; no price, procurement mechanism or comparative cost is supplied.[18]
• Recognise that hypertension services are characterised as accessible, simple and affordable for integration into primary health systems, without an accompanying costing methodology or financial value.[10]
• Record that no explicit costs, budget lines, financing sources, funding gaps or economic assumptions are supplied for diabetes, TB and HIV integration, asthma services, hypertension management or cardiovascular care.[17][39][5][6][7][8][12][21]